Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Hydroxycarbamid (ausschl. Dafo. FTA), ATC L01XX05 f. d. Z. 01.08.2026 - 31.07.2028 (zzgl. V.-Option 1x12 Mon)

Section 130a, paragraph 8, of the German Social Code (SGB V) allows health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the German Act Against Restraints of Competition (GWB). For pharmaceuticals to be specified by the bidder in more detail in Annex 2 to the contract, for the above-mentioned active substance Hydroxycarbamide (exclusively in the form of FTA), ATC L01XX05, the DAK-Gesundheit intends to conclude pharmaceutical discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical discount contracts. A discount contract under the licensing model for the above-mentioned active substance will come into force for the first time on 01.08.2026 and will end on 31.07.2028 (plus extension option 1x12 months). It will automatically end with the entry into force of the exclusive contract.